EXCLUSION CRITERIA FOR SECOND-LINE THERAPY: Anticipated patient survival under 2 months
Anticipated survival minimum of 12 months.
Anticipated survival of < 3 months
Major anticipated illness or organ failure incompatible with survival from bone marrow transplantation (BMT).
Anticipated survival of < 3 months
Participants with a serious medical illness that may limit survival to less than 3 months
Must have an anticipated survival of at least 12 weeks.
Anticipated survival of at least 3 months
Major anticipated illness or organ failure incompatible with survival from bone marrow transplant (BMT)
Predicted survival of > 6 months
Anticipated survival of at least 6 months
Major anticipated illness or organ failure incompatible with survival form transplant
Major anticipated illness or organ failure incompatible with survival from peripheral blood stem cell (PBSC) transplant
An anticipated overall survival of at least 6 months
Anticipated patient survival under 3 months
Patients must have a reasonable expectation of ? 6 months survival
Anticipated survival of at least 3 months
Anticipated patient survival under 3 months
Anticipated lifespan greater than 3 months
Anticipated survival of at least 6 months
Anticipated survival of less than 1 month
Anticipated patient survival under 3 months
Presence of any other medical complications that imply a survival of less than six months
Anticipated patient survival under 2 months
Anticipated survival of at least 6 months
Anticipated survival of at least 3 months
Anticipated patient survival under 3 months
Anticipated survival under 3 months
Survival less than 12 months after surgery (either predicted survival before surgery or actual survival after surgery < 12 months)
If survival is deemed less than 6 months for any medical condition
Patients should, in the estimate of the treating physicians, be anticipated to have a median survival of > 1 year
Diagnosed with stage I or II pancreatic cancer or with anticipated survival of less than three months
Anticipated survival less than 5 years, as per the treating physician
Patients must have an estimated survival greater or equal to 3 months
Participants with active infection(s) for which they are receiving drug treatment unless the clinical status is judged to be stable and survival is estimated to be at least 6 weeks
ECOG performance status of 0 - 2 and estimated survival of at least 3 months
Estimated survival of at least 12 weeks;
For known primary, disease-specific graded prognostic assessment (ds-GPA) estimated median survival no less than 6 months
For unknown primary, graded prognostic assessment (GPA) estimated median survival no less than 6 months
Patients who have a known primary and have an estimated median survival less than 6 months per ds-GPA
Patients who have an unknown primary and have an estimated median survival less than 6 months per GPA
Estimated survival >= 3 months
Surgeon's estimated survival >= 1 month
Estimated survival < 1 month
Patients with an estimated survival of less than three months.
Estimated survival of at least 8 weeks
Estimated survival of at least 3 months
Estimated survival ? 6 months.
An estimated progression-free survival of less than one year
Patients must have an estimated survival greater than or equal to 3 months
Estimated >4 months survival probability.
Estimated >4 month survival probability.
Patients with an estimated survival of less than one year are not eligible
Probability of survival is at least 6 months
Patients with an ECOG performance status of 0, 1, or 2, and estimated survival of > 12 weeks.
Estimated survival of at least 6 months.
Patient may have distant metastatic disease provided the estimated survival is at least 1 year